PARIS (March 29, 2018) – International law firm McDermott Will & Emery advised DBV Technologies (DBV) - a French clinical-stage biopharmaceutical company, on its capital increase by public offering in the United States, Canada and certain other countries outside Europe and by private placement in Europe (including in France).

DBV, listed on Euronext Paris and on the Nasdaq, raised 140.8 million euros following the exercise of the over-allotment option.

DBV is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy.

The McDermott team led by partners Emmanuelle Trombe and Bertrand Delafaye, included Aymeric Discours, Mathilde Peschard, Anaël Hadji, Stephan de Groër, Antoine Vergnat and Côme de Saint-Vincent.